Caprariello, Andrew V. http://orcid.org/0000-0002-2529-5621
Adams, Drew J. http://orcid.org/0000-0002-3038-336X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS115867)
G. Harold and Leila Y. Mathers Foundation (none)
Edward Mallinckrodt, Jr. Foundation (none)
Conrad N. Hilton Foundation (none)
National Multiple Sclerosis Society (none)
Article History
Received: 14 December 2021
Accepted: 18 July 2022
First Online: 22 August 2022
Competing interests
: The authors declare the following competing interests: D.J.A. is a founder, consultant, director, and shareholder of Convelo Therapeutics, which seeks to develop remyelinating therapeutics. D.J.A., is an inventor on patents and patent applications that have been licensed to Convelo. A.V.C. is an employee of Convelo Therapeutics. Convelo has not provided any support to the Adams Lab.